This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance treatment options for patients with cancer.View NLNK key stats
NewLink Genetics Corp - NLNK - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates NewLink Genetics Corp as a
Buy with a ratings score of B-.
Report Snippet: We rate NEWLINK GENETICS CORP (NLNK) a BUY. This is driven by a few notable strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.